Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats
- PMID: 2969304
- DOI: 10.1007/BF00254172
Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats
Abstract
Uridine (UR) inhibits the metabolic activation of 5'-deoxy-5-fluorouridine (dFUR) to 5-fluorouracil (FU) by the intestinal pyrimidine nucleoside phosphorylases and could potentially reduce its intestinal toxicity. This study examined the effect of UR coadministration on the absorption and disposition of an oral dose of dFUR. Rats were given dFUR alone (500 mg kg-1) and dFUR (300 mg kg-1) plus UR (4.5 g kg-1) in a random crossover experiment. Simultaneous injection of a tracer dose of [6-3H]dFUR was used to asses the total body clearance (Cl) of dFUR. The absorption of UR was rapid and variable. The UR dose produced a maximal blood concentration of 80 micrograms/ml for UR and 100 micrograms/ml for its metabolite uracil (U). The absorption of dFUR was slower than UR, as indicated by its later time of maximal concentration. UR did not alter the Cl of dFUR, but reduced the absorption rate of dFUR from the gastrointestinal tract and significantly reduced the absolute oral bioavailability of dFUR from 55.2% to 33.4%. The effects of UR coadministration on the dFUR metabolite FU were opposite to those on dFUR; the FU availability was increased sixfold, and the elimination of FU was reduced. Based on the known competition between pyrimidine bases for their saturable metabolic enzymes, the increase in FU availability by UR coadministration was likely due to a competitive inhibition of FU metabolism by U. This study established the complex pharmacokinetic interactions between dFUR and UR and between their metabolites, which may be important in the modulation of dFUR activity by UR.
Similar articles
-
Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.Pharm Res. 1998 Jul;15(7):1007-11. doi: 10.1023/a:1011917824836. Pharm Res. 1998. PMID: 9688052
-
Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats.J Pharm Sci. 1987 Sep;76(9):699-702. doi: 10.1002/jps.2600760906. J Pharm Sci. 1987. PMID: 11002805
-
Inhibition of intestinal pyrimidine nucleoside phosphorylases.Pharm Res. 1987 Oct;4(5):425-8. doi: 10.1023/a:1016446715114. Pharm Res. 1987. PMID: 2977647
-
Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.Biol Pharm Bull. 1993 Dec;16(12):1297-300. doi: 10.1248/bpb.16.1297. Biol Pharm Bull. 1993. PMID: 8130783
-
Modulation of fluorouracil toxicity with uridine.Semin Oncol. 1992 Apr;19(2 Suppl 3):148-54. Semin Oncol. 1992. PMID: 1557641 Review.
Cited by
-
Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.Cancer Chemother Pharmacol. 1989;24(1):9-14. doi: 10.1007/BF00254098. Cancer Chemother Pharmacol. 1989. PMID: 2720896
-
Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.Pharm Res. 1998 Jul;15(7):1007-11. doi: 10.1023/a:1011917824836. Pharm Res. 1998. PMID: 9688052
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources